DPYD基因的三种不同多态性与5-氟尿嘧啶给药后的严重毒性相关：一例报告。
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
作者信息
Mukherji Deborah, Massih Sarah Abdel, Tfayli Arafat, Kanso Mariam, Faraj Walid
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Department of Surgery, HPB and Liver Transplant Unit, American University of Beirut, PO Box 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon.
出版信息
J Med Case Rep. 2019 Mar 22;13(1):76. doi: 10.1186/s13256-019-2013-z.
Abstract
BACKGROUND
Dihydropyrimidine dehydrogenase deficiency secondary to polymorphisms in the DPYD gene can lead to significant toxicity associated with the administration of fluoropyrimidine chemotherapy.
CASE PRESENTATION
We report a case of a 59-year-old Lebanese woman with metastatic pancreatic cancer who received FOLFIRINOX therapy and developed severe 5-fluorouracil toxicity after a single cycle. The entire DPYD gene was sequenced, and the patient was found to be heterozygous for three different polymorphisms that have reportedly been associated with dihydropyrimidine dehydrogenase deficiency.
CONCLUSION
Because data regarding the prevalence and clinical significance of several heterozygous polymorphisms in a single DPYD gene are very limited, we suggest that full gene sequencing should be carried out, at least in populations in which the allele frequencies are unknown.
摘要
背景
由于二氢嘧啶脱氢酶（DPYD）基因多态性继发的二氢嘧啶脱氢酶缺乏症，可导致与氟嘧啶化疗给药相关的显著毒性。
病例报告
我们报告了一例59岁的黎巴嫩转移性胰腺癌女性患者，其接受了FOLFIRINOX治疗，在一个疗程后出现了严重的5-氟尿嘧啶毒性。对整个DPYD基因进行了测序，发现该患者存在三种不同的多态性，据报道这些多态性与二氢嘧啶脱氢酶缺乏症有关，且为杂合子。
结论
由于关于单个DPYD基因中几种杂合多态性的患病率和临床意义的数据非常有限，我们建议至少在等位基因频率未知的人群中进行全基因测序。
相似文献
1
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.DPYD基因的三种不同多态性与5-氟尿嘧啶给药后的严重毒性相关：一例报告。
J Med Case Rep. 2019 Mar 22;13(1):76. doi: 10.1186/s13256-019-2013-z.
2
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.三醋酸尿苷（Vistogard）在挽救二氢嘧啶脱氢酶（DPYD）缺乏患者严重5-氟尿嘧啶毒性方面的益处。
Cancer Chemother Pharmacol. 2016 Jul;78(1):151-6. doi: 10.1007/s00280-016-3063-1. Epub 2016 Jun 8.
3
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].[二氢嘧啶脱氢酶（DPD）缺乏症筛查与基于氟嘧啶的化疗保障：法国GPCO-法国国立癌症研究所联盟和RNPGx网络的更新与建议]
Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24.
4
A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.一个新的 DPYD 基因内大片段缺失导致二氢嘧啶脱氢酶缺乏症：病例报告。
BMC Med Genomics. 2024 Mar 25;17(1):78. doi: 10.1186/s12920-024-01846-2.
5
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.基于 DPYD 基因型的氟嘧啶类药物个体化剂量在癌症患者中的应用：一项前瞻性安全性分析。
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
6
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.携 DPYD*9A(c.85T>C) 基因型的胃肠道恶性肿瘤患者接受氟嘧啶类药物治疗的流行率及基因型-表型相关性：更新分析。
Clin Colorectal Cancer. 2019 Sep;18(3):e280-e286. doi: 10.1016/j.clcc.2019.04.005. Epub 2019 May 3.
7
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.携带 DPYD*2A 变异的患者中低剂量氟嘧啶治疗的有效性和安全性：一项配对分析。
Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.
8
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.在放化疗中使用标准氟嘧啶剂量会增加 DPYD 变异等位基因携带者发生严重毒性的风险。
Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.
9
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.由于影响 DPD 活性和 mRNA 剪接的新型和罕见 DPYD 错义突变、缺失和基因组扩增导致严重的氟尿嘧啶毒性。
Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):721-730. doi: 10.1016/j.bbadis.2016.12.010. Epub 2016 Dec 24.
10
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.双氢嘧啶脱氢酶（DPYD）基因c.1129-5923C>G纯合子/单倍型B3的患者存在部分双氢嘧啶脱氢酶缺乏，在接受氟嘧啶治疗时需要减少剂量。
Cancer Chemother Pharmacol. 2016 Oct;78(4):875-80. doi: 10.1007/s00280-016-3137-0. Epub 2016 Aug 20.
引用本文的文献
1
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.非欧洲严重氟嘧啶相关毒性患者的 DPYD 基因多态性：系统评价。
Br J Cancer. 2024 Aug;131(3):498-514. doi: 10.1038/s41416-024-02754-z. Epub 2024 Jun 17.
2
Pharmacogenomics in Lebanon: current status, challenges and opportunities.黎巴嫩的药物基因组学：现状、挑战与机遇
Pharmacogenomics J. 2024 May 22;24(3):16. doi: 10.1038/s41397-024-00336-z.
3
Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment.结肠癌治疗中5-氟尿嘧啶耐药机制及逆转策略的最新进展
Biology (Basel). 2021 Aug 31;10(9):854. doi: 10.3390/biology10090854.
4
Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature.氟嘧啶诱导的严重毒性与罕见的二氢嘧啶脱氢酶（DPYD）基因多态性相关：沙特阿拉伯的病例系列及文献综述
Clin Pract. 2021 Jul 27;11(3):467-471. doi: 10.3390/clinpract11030062.
5
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?二氢嘧啶脱氢酶缺乏症：筛查还是不筛查？
J Adv Pract Oncol. 2020 Jan-Feb;11(1):68-73. doi: 10.6004/jadpro.2020.11.1.4. Epub 2020 Jan 1.
6
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.胰腺癌患者接受 mFOLFIRINOX 或吉西他滨联合 nab-紫杉醇治疗时 DPYD、UGT、CDA 和 ABCB1 多态性的综合遗传药理学分析。
Pharmacogenomics J. 2021 Apr;21(2):233-242. doi: 10.1038/s41397-020-00203-7. Epub 2021 Jan 18.
7
Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine.氟嘧啶化学在个性化医学时代。
Molecules. 2020 Jul 29;25(15):3438. doi: 10.3390/molecules25153438.
本文引用的文献
1
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.DPYD 变异 c.1679T>G、c.1236G>A/HapB3 和 c.1601G>A 作为预测氟嘧啶类药物相关严重毒性的指标的临床意义：一项基于个体患者数据的系统评价和荟萃分析。
Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23.
2
DPD deficiency in patients treated with fluorouracil.接受氟尿嘧啶治疗患者的二氢嘧啶脱氢酶缺乏症
Lancet Oncol. 2015 Dec;16(16):1574-6. doi: 10.1016/S1470-2045(15)00360-5. Epub 2015 Oct 23.
3
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. upfront 基因分型 DPYD*2A 以实现氟尿嘧啶类药物个体化治疗：安全性和成本分析。
J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.
4
Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis.DPYD基因多态性对结直肠癌患者5-氟尿嘧啶毒性的影响：一项荟萃分析
Gastroenterol Res Pract. 2014;2014:827989. doi: 10.1155/2014/827989. Epub 2014 Dec 28.
5
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.DPYD IVS14+1G＞A 和 2846A＞T 基因分型预测严重氟尿嘧啶相关毒性的荟萃分析。
Pharmacogenomics. 2013 Aug;14(11):1255-72. doi: 10.2217/pgs.13.116.
6
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China.评价二氢嘧啶脱氢酶基因单核苷酸多态性对中国 60 例结直肠癌患者氟尿嘧啶毒性的临床价值。
Int J Med Sci. 2013 May 20;10(7):894-902. doi: 10.7150/ijms.5556. Print 2013.
7
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.DPYD、TYMS、CDA 和 MTHFR 基因中的药物遗传学变异是氟嘧啶类毒性的临床显著预测因子。
Br J Cancer. 2013 Jun 25;108(12):2505-15. doi: 10.1038/bjc.2013.262. Epub 2013 Jun 4.
8
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.伊立替康治疗转移性结直肠癌的毒性和疗效预测因素。
Acta Medica (Hradec Kralove). 2012;55(4):153-9. doi: 10.14712/18059694.2015.39.
9
Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.一组土耳其结直肠癌患者中DPYD基因IVS14+1G>A多态性的研究。
Anticancer Res. 2007 Nov-Dec;27(6B):3899-902.
10
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.对接受5-氟尿嘧啶/卡培他滨治疗的癌症患者二氢嘧啶脱氢酶缺乏症的分析
Clin Colorectal Cancer. 2006 Nov;6(4):288-96. doi: 10.3816/CCC.2006.n.047.
Zotero 插件